Hormone or androgen-deprivation therapy (ADT), which acts to suppress the androgen receptor (AR) signaling by androgen depletion or AR antagonists, is still the principal treatment option for locally advanced and metastatic prostate cancers. The gene discussed is AR; the disease is Familial prostate cancer.